<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Anti-arrhythmics: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i116.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i116.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i116.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i115.htm" title="Previous: Sodium Bicarbonate">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i1176.htm" title="Next: Dronedarone">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i116">Anti-arrhythmics</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Anti-arrhythmics</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i116.htm">Anti-arrhythmics</a></td><td class="cBV"><b>increased myocardial depression when  anti-arrhythmics given with other anti-arrhythmics </b></td><td></td></tr><tr><td><a href="41001i363.htm" name="_363">Antipsychotics</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  anti-arrhythmics that prolong the QT interval given with antipsychotics that prolong the QT interval</b></td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i440.htm" name="_440">Beta-blockers</a></td><td class="cBV"><b>increased myocardial depression when  anti-arrhythmics given with beta-blockers </b></td><td>Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</td></tr><tr><td><a href="41001i54.htm" name="_54">Bupivacaine</a></td><td>increased myocardial depression when  anti-arrhythmics given with bupivacaine </td><td></td></tr><tr><td><a href="41001i906.htm" name="_906">Levobupivacaine</a></td><td>increased myocardial depression when  anti-arrhythmics given with levobupivacaine </td><td></td></tr><tr><td><a href="41001i873.htm" name="_873">Prilocaine</a></td><td>increased myocardial depression when  anti-arrhythmics given with prilocaine </td><td></td></tr><tr><td><a href="41001i888.htm" name="_888">Ropivacaine</a></td><td>increased myocardial depression when  anti-arrhythmics given with ropivacaine </td><td></td></tr></tbody></table><p><b>Dronedarone</b> belongs to
      <b>Anti-arrhythmics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



































<tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  dronedarone given with amiodarone—avoid concomitant use</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td class="cBV"><b>manufacturer of  dronedarone advises avoid concomitant use with tricyclics (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td> dronedarone possibly increases plasma concentration of atorvastatin </td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b>plasma concentration of  dronedarone possibly reduced by carbamazepine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>manufacturer of  dronedarone advises avoid concomitant use with clarithromycin (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> dronedarone possibly enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i1120.htm">Dabigatran Etexilate</a></td><td class="cBV"><b> dronedarone increases plasma concentration of dabigatran etexilate—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td class="cBV"><b> dronedarone increases plasma concentration of digoxin (halve dose of digoxin)</b></td><td></td></tr><tr><td><a href="41001i468.htm">Diltiazem</a></td><td class="cBV"><b>increased risk of bradycardia and myocardial depression when  dronedarone given with diltiazem </b></td><td></td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  dronedarone given with disopyramide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>plasma concentration of  dronedarone increased by erythromycin (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i1202.htm">Fingolimod</a></td><td class="cBV"><b>possible increased risk of bradycardia when  dronedarone given with fingolimod </b></td><td></td></tr><tr><td><a href="41001i829.htm">Grapefruit Juice</a></td><td class="cBV"><b>plasma concentration of  dronedarone increased by grapefruit juice—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b>manufacturer of  dronedarone advises avoid concomitant use with itraconazole </b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>plasma concentration of  dronedarone increased by ketoconazole—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i451.htm">Metoprolol</a></td><td> dronedarone possibly increases plasma concentration of metoprolol </td><td></td></tr><tr><td><a href="41001i475.htm">Nifedipine</a></td><td class="cBV"><b>plasma concentration of  dronedarone increased by nifedipine </b></td><td></td></tr><tr><td><a href="41001i223.htm">Phenindione</a></td><td class="cBV"><b> dronedarone possibly enhances anticoagulant effect of phenindione </b></td><td>Change in patient’s clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td class="cBV"><b>plasma concentration of  dronedarone possibly reduced by phenobarbital—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i373.htm">Phenothiazines</a></td><td class="cBV"><b>manufacturer of  dronedarone advises avoid concomitant use with phenothiazines (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b>plasma concentration of  dronedarone possibly reduced by phenytoin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1060.htm">Posaconazole</a></td><td class="cBV"><b>manufacturer of  dronedarone advises avoid concomitant use with posaconazole </b></td><td></td></tr><tr><td><a href="41001i793.htm">Propranolol</a></td><td> dronedarone possibly increases plasma concentration of propranolol </td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  dronedarone reduced by rifampicin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>manufacturer of  dronedarone advises avoid concomitant use with ritonavir </b></td><td></td></tr><tr><td><a href="41001i974.htm">Rosuvastatin</a></td><td> dronedarone possibly increases plasma concentration of rosuvastatin </td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  dronedarone given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  dronedarone given with simvastatin </b></td><td></td></tr><tr><td><a href="41001i921.htm">Sirolimus</a></td><td>manufacturer of  dronedarone advises caution with sirolimus </td><td></td></tr><tr><td><a href="41001i455.htm">Sotalol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  dronedarone given with sotalol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  dronedarone possibly reduced by St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td>manufacturer of  dronedarone advises caution with tacrolimus </td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>manufacturer of  dronedarone advises avoid concomitant use with telithromycin (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td class="cBV"><b>increased risk of bradycardia and myocardial depression when  dronedarone given with verapamil </b></td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b>manufacturer of  dronedarone advises avoid concomitant use with voriconazole </b></td><td></td></tr></tbody></table><p><b>Adenosine</b> belongs to
      <b>Anti-arrhythmics</b>
          and has the following interaction information:
        </p><div>Possibility of interaction with drugs tending to impair myocardial conduction</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i362.htm">Dipyridamole</a></td><td class="cBV"><b>effect of  adenosine enhanced and extended by dipyridamole (important risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i1082.htm">Nicotine</a></td><td>effects of  adenosine possibly enhanced by nicotine </td><td></td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td>anti-arrhythmic effect of  adenosine antagonised by theophylline </td><td></td></tr></tbody></table><p><b>Amiodarone</b> belongs to
      <b>Anti-arrhythmics</b>
          and has the following interaction information:
        </p><div>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

























































<tr><td><a href="41001i551.htm">Acetazolamide</a></td><td>increased cardiac toxicity with  amiodarone if hypokalaemia occurs with acetazolamide </td><td></td></tr><tr><td><a href="41001i1012.htm">Agalsidase Alfa and Beta</a></td><td> amiodarone possibly inhibits effects of agalsidase alfa and beta (manufacturers of agalsidase alfa and beta advise avoid concomitant use)</td><td></td></tr><tr><td><a href="41001i809.htm">Amisulpride</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with amisulpride—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with tricyclics—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1168.htm">Arsenic Trioxide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with arsenic trioxide </b></td><td></td></tr><tr><td><a href="41001i937.htm">Artemether with Lumefantrine</a></td><td class="cBV"><b>avoidance of  amiodarone advised by manufacturer of artemether/lumefantrine (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>plasma concentration of  amiodarone possibly increased by atazanavir </b></td><td></td></tr><tr><td><a href="41001i1009.htm">Atomoxetine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with atomoxetine </b></td><td></td></tr><tr><td><a href="41001i385.htm">Benperidol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with benperidol—manufacturer of benperidol advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i440.htm">Beta-blockers</a></td><td class="cBV"><b>increased risk of bradycardia, AV block and myocardial depression when  amiodarone given with beta-blockers </b></td><td>Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</td></tr><tr><td><a href="41001i335.htm">Chloroquine and Hydroxychloroquine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with chloroquine and hydroxychloroquine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td> amiodarone possibly increases plasma concentration of ciclosporin </td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>plasma concentration of  amiodarone increased by cimetidine </td><td></td></tr><tr><td><a href="41001i483.htm">Colchicine</a></td><td class="cBV"><b> amiodarone possibly increases risk of colchicine toxicity</b></td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> amiodarone inhibits metabolism of coumarins (enhanced anticoagulant effect)</b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i1120.htm">Dabigatran Etexilate</a></td><td class="cBV"><b> amiodarone increases plasma concentration of dabigatran etexilate (reduce dose of dabigatran etexilate)</b></td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td class="cBV"><b> amiodarone increases plasma concentration of digoxin (halve dose of digoxin)</b></td><td></td></tr><tr><td><a href="41001i468.htm">Diltiazem</a></td><td class="cBV"><b>increased risk of bradycardia, AV block and myocardial depression when  amiodarone given with diltiazem </b></td><td></td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with disopyramide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i539.htm">Diuretics, Loop</a></td><td>increased cardiac toxicity with  amiodarone if hypokalaemia occurs with loop diuretics </td><td></td></tr><tr><td><a href="41001i525.htm">Diuretics, Thiazide and related</a></td><td>increased cardiac toxicity with  amiodarone if hypokalaemia occurs with thiazides and related diuretics </td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with dronedarone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1152.htm">Droperidol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with droperidol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1025.htm">Eplerenone</a></td><td> amiodarone increases plasma concentration of eplerenone (reduce dose of eplerenone)</td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with <i>parenteral</i> erythromycin—avoid concomitant use</b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i1202.htm">Fingolimod</a></td><td class="cBV"><b>possible increased risk of bradycardia when  amiodarone given with fingolimod </b></td><td></td></tr><tr><td><a href="41001i120.htm">Flecainide</a></td><td class="cBV"><b> amiodarone increases plasma concentration of flecainide (halve dose of flecainide)</b></td><td></td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td class="cBV"><b>plasma concentration of  amiodarone possibly increased by fosamprenavir (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i829.htm">Grapefruit Juice</a></td><td>plasma concentration of  amiodarone increased by grapefruit juice </td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with haloperidol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b>plasma concentration of  amiodarone possibly increased by indinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1050.htm">Ivabradine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with ivabradine </b></td><td></td></tr><tr><td><a href="41001i840.htm">Levofloxacin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with levofloxacin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i372.htm">Lithium</a></td><td class="cBV"><b>manufacturer of  amiodarone advises avoid concomitant use with lithium (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i337.htm">Mefloquine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with mefloquine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i841.htm">Mizolastine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with mizolastine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i973.htm">Moxifloxacin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with moxifloxacin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with nelfinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i856.htm">Orlistat</a></td><td>plasma concentration of  amiodarone possibly reduced by orlistat </td><td></td></tr><tr><td><a href="41001i808.htm">Pentamidine Isetionate</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with pentamidine isetionate—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i223.htm">Phenindione</a></td><td class="cBV"><b> amiodarone inhibits metabolism of phenindione (enhanced anticoagulant effect)</b></td><td>Change in patient’s clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </td></tr><tr><td><a href="41001i373.htm">Phenothiazines</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with phenothiazines—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b> amiodarone inhibits metabolism of phenytoin (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with pimozide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i341.htm">Quinine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with quinine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  amiodarone increased by ritonavir (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  amiodarone given with simvastatin </b></td><td></td></tr><tr><td><a href="41001i455.htm">Sotalol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with sotalol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i208.htm">Sulfamethoxazole</a></td><td>possible increased risk of ventricular arrhythmias when  amiodarone given with sulfamethoxazole (as co-trimoxazole)—manufacturer of amiodarone advises avoid concomitant use of co-trimoxazole</td><td></td></tr><tr><td><a href="41001i371.htm">Sulpiride</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with sulpiride </b></td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>avoidance of  amiodarone advised by manufacturer of telaprevir (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i935.htm">Thyroid Hormones</a></td><td>for concomitant use of  amiodarone and thyroid hormones see <a title="target-block: amiodarone thyroid" href="2416.htm#_2416.2">section 2.3.2</a></td><td></td></tr><tr><td><a href="41001i850.htm">Tolterodine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with tolterodine </b></td><td></td></tr><tr><td><a href="41001i217.htm">Trimethoprim</a></td><td>possible increased risk of ventricular arrhythmias when  amiodarone given with trimethoprim (as co-trimoxazole)—manufacturer of amiodarone advises avoid concomitant use of co-trimoxazole</td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td class="cBV"><b>increased risk of bradycardia, AV block and myocardial depression when  amiodarone given with verapamil </b></td><td></td></tr><tr><td><a href="41001i390.htm">Zuclopenthixol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amiodarone given with zuclopenthixol—avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Disopyramide</b> belongs to
      <b>Anti-arrhythmics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>













































<tr><td><a href="41001i551.htm">Acetazolamide</a></td><td class="cBV"><b>increased cardiac toxicity with  disopyramide if hypokalaemia occurs with acetazolamide </b></td><td></td></tr><tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with amiodarone—avoid concomitant use</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i809.htm">Amisulpride</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with amisulpride—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with tricyclics </b></td><td></td></tr><tr><td><a href="41001i342.htm">Antimuscarinics</a></td><td>increased risk of antimuscarinic side-effects when  disopyramide given with antimuscarinics </td><td>Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</td></tr><tr><td><a href="41001i1168.htm">Arsenic Trioxide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with arsenic trioxide </b></td><td></td></tr><tr><td><a href="41001i937.htm">Artemether with Lumefantrine</a></td><td class="cBV"><b>avoidance of  disopyramide advised by manufacturer of artemether/lumefantrine (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i1009.htm">Atomoxetine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with atomoxetine </b></td><td></td></tr><tr><td><a href="41001i167.htm">Azithromycin</a></td><td class="cBV"><b>plasma concentration of  disopyramide possibly increased by azithromycin (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>plasma concentration of  disopyramide possibly increased by clarithromycin (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i539.htm">Diuretics, Loop</a></td><td class="cBV"><b>increased cardiac toxicity with  disopyramide if hypokalaemia occurs with loop diuretics </b></td><td></td></tr><tr><td><a href="41001i525.htm">Diuretics, Thiazide and related</a></td><td class="cBV"><b>increased cardiac toxicity with  disopyramide if hypokalaemia occurs with thiazides and related diuretics </b></td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with dronedarone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1152.htm">Droperidol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with droperidol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>plasma concentration of  disopyramide increased by erythromycin (increased risk of toxicity)</b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i1202.htm">Fingolimod</a></td><td class="cBV"><b>possible increased risk of bradycardia when  disopyramide given with fingolimod </b></td><td></td></tr><tr><td><a href="41001i271.htm">Gliclazide</a></td><td> disopyramide possibly enhances hypoglycaemic effect of gliclazide </td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td class="cBV"><b>possible increased risk of ventricular arrhythmias when  disopyramide given with haloperidol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i265.htm">Insulin</a></td><td> disopyramide possibly enhances hypoglycaemic effect of insulin </td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b>avoidance of  disopyramide advised by manufacturer of itraconazole </b></td><td></td></tr><tr><td><a href="41001i1050.htm">Ivabradine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with ivabradine </b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with ketoconazole—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i267.htm">Metformin</a></td><td> disopyramide possibly enhances hypoglycaemic effect of metformin </td><td></td></tr><tr><td><a href="41001i841.htm">Mizolastine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with mizolastine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i973.htm">Moxifloxacin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with moxifloxacin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i631.htm">Nitrates</a></td><td> disopyramide reduces effects of sublingual tablets of nitrates (failure to dissolve under tongue owing to dry mouth)</td><td></td></tr><tr><td><a href="41001i808.htm">Pentamidine Isetionate</a></td><td class="cBV"><b>possible increased risk of ventricular arrhythmias when  disopyramide given with pentamidine isetionate </b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>metabolism of  disopyramide accelerated by phenobarbital (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i373.htm">Phenothiazines</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with phenothiazines </b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>plasma concentration of  disopyramide reduced by phenytoin </td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with pimozide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td class="cBV"><b>avoidance of  disopyramide advised by manufacturer of ranolazine </b></td><td></td></tr><tr><td><a href="41001i199.htm">Rifamycins</a></td><td class="cBV"><b>metabolism of  disopyramide accelerated by rifamycins (reduced plasma concentration)</b></td><td>Interactions do not apply to rifaximin</td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  disopyramide possibly increased by ritonavir (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i858.htm">Sildenafil</a></td><td>manufacturer of  disopyramide advises avoid concomitant use with sildenafil (risk of ventricular arrhythmias)</td><td></td></tr><tr><td><a href="41001i455.htm">Sotalol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with sotalol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i371.htm">Sulpiride</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with sulpiride </b></td><td></td></tr><tr><td><a href="41001i945.htm">Tadalafil</a></td><td>manufacturer of  disopyramide advises avoid concomitant use with tadalafil (risk of ventricular arrhythmias)</td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>avoidance of  disopyramide advised by manufacturer of telaprevir (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i850.htm">Tolterodine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with tolterodine </b></td><td></td></tr><tr><td><a href="41001i967.htm">Vardenafil</a></td><td>manufacturer of  disopyramide advises avoid concomitant use with vardenafil (risk of ventricular arrhythmias)</td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td class="cBV"><b>increased risk of myocardial depression and asystole when  disopyramide given with verapamil </b></td><td></td></tr><tr><td><a href="41001i222.htm">Warfarin</a></td><td> disopyramide may enhance or reduce anticoagulant effect of warfarin </td><td></td></tr><tr><td><a href="41001i390.htm">Zuclopenthixol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  disopyramide given with zuclopenthixol—avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Flecainide</b> belongs to
      <b>Anti-arrhythmics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




















<tr><td><a href="41001i551.htm">Acetazolamide</a></td><td class="cBV"><b>increased cardiac toxicity with  flecainide if hypokalaemia occurs with acetazolamide </b></td><td></td></tr><tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>plasma concentration of  flecainide increased by amiodarone (halve dose of flecainide)</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  flecainide given with tricyclics </b></td><td></td></tr><tr><td><a href="41001i937.htm">Artemether with Lumefantrine</a></td><td class="cBV"><b>avoidance of  flecainide advised by manufacturer of artemether/lumefantrine (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i440.htm">Beta-blockers</a></td><td class="cBV"><b>increased risk of myocardial depression and bradycardia when  flecainide given with beta-blockers </b></td><td>Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>metabolism of  flecainide inhibited by cimetidine (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b>increased risk of arrhythmias when  flecainide given with clozapine </b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i539.htm">Diuretics, Loop</a></td><td class="cBV"><b>increased cardiac toxicity with  flecainide if hypokalaemia occurs with loop diuretics </b></td><td></td></tr><tr><td><a href="41001i525.htm">Diuretics, Thiazide and related</a></td><td class="cBV"><b>increased cardiac toxicity with  flecainide if hypokalaemia occurs with thiazides and related diuretics </b></td><td></td></tr><tr><td><a href="41001i234.htm">Fluoxetine</a></td><td>plasma concentration of  flecainide increased by fluoxetine </td><td></td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td class="cBV"><b>plasma concentration of  flecainide possibly increased by fosamprenavir (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b>plasma concentration of  flecainide possibly increased by indinavir (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td class="cBV"><b>plasma concentration of  flecainide possibly increased by lopinavir (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i841.htm">Mizolastine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  flecainide given with mizolastine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i341.htm">Quinine</a></td><td class="cBV"><b>plasma concentration of  flecainide increased by quinine </b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  flecainide possibly increased by ritonavir (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  flecainide given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>caution with  flecainide advised by manufacturer of telaprevir (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i850.htm">Tolterodine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  flecainide given with tolterodine </b></td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td class="cBV"><b>increased risk of myocardial depression and asystole when  flecainide given with verapamil </b></td><td></td></tr></tbody></table><p><b>Lidocaine</b> belongs to
      <b>Anti-arrhythmics</b>
          and has the following interaction information:
        </p><div>Interactions less likely when lidocaine used topically</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>












<tr><td><a href="41001i551.htm">Acetazolamide</a></td><td class="cBV"><b>action of  lidocaine antagonised by hypokalaemia caused by acetazolamide </b></td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>plasma concentration of  lidocaine possibly increased by atazanavir </b></td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td class="cBV"><b>plasma concentration of  lidocaine increased by cimetidine (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td>plasma concentration of  lidocaine possibly increased by darunavir—avoid concomitant use</td><td></td></tr><tr><td><a href="41001i539.htm">Diuretics, Loop</a></td><td class="cBV"><b>action of  lidocaine antagonised by hypokalaemia caused by loop diuretics </b></td><td></td></tr><tr><td><a href="41001i525.htm">Diuretics, Thiazide and related</a></td><td class="cBV"><b>action of  lidocaine antagonised by hypokalaemia caused by thiazides and related diuretics </b></td><td></td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td class="cBV"><b>plasma concentration of  lidocaine possibly increased by fosamprenavir—avoid concomitant use</b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td>plasma concentration of  lidocaine possibly increased by lopinavir </td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i793.htm">Propranolol</a></td><td class="cBV"><b>increased risk of  lidocaine toxicity when given with propranolol </b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  lidocaine given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i628.htm">Suxamethonium</a></td><td>neuromuscular blockade enhanced and prolonged when  lidocaine given with suxamethonium </td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td>caution with <i>intravenous</i>  lidocaine advised by manufacturer of telaprevir </td><td></td></tr></tbody></table><p><b>Propafenone</b> belongs to
      <b>Anti-arrhythmics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

















<tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td class="cBV"><b>increased risk of arrhythmias when  propafenone given with tricyclics </b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td> propafenone possibly increases plasma concentration of ciclosporin </td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td class="cBV"><b>plasma concentration of  propafenone increased by cimetidine </b></td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> propafenone enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td class="cBV"><b> propafenone increases plasma concentration of digoxin (halve dose of digoxin)</b></td><td></td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td class="cBV"><b>plasma concentration of  propafenone possibly increased by fosamprenavir (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i451.htm">Metoprolol</a></td><td> propafenone increases plasma concentration of metoprolol </td><td></td></tr><tr><td><a href="41001i841.htm">Mizolastine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  propafenone given with mizolastine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i647.htm">Neostigmine</a></td><td> propafenone possibly antagonises effects of neostigmine </td><td></td></tr><tr><td><a href="41001i236.htm">Paroxetine</a></td><td>metabolism of  propafenone possibly inhibited by paroxetine (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i793.htm">Propranolol</a></td><td> propafenone increases plasma concentration of propranolol </td><td></td></tr><tr><td><a href="41001i648.htm">Pyridostigmine</a></td><td> propafenone possibly antagonises effects of pyridostigmine </td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>metabolism of  propafenone accelerated by rifampicin (reduced effect)</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  propafenone increased by ritonavir (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  propafenone given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>caution with  propafenone advised by manufacturer of telaprevir (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td> propafenone increases plasma concentration of theophylline </td><td></td></tr></tbody></table></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i1176.htm" title="Dronedarone">Dronedarone</a></li><li><a href="41001i117.htm" title="Adenosine">Adenosine</a></li><li><a href="41001i118.htm" title="Amiodarone">Amiodarone</a></li><li><a href="41001i119.htm" title="Disopyramide">Disopyramide</a></li><li><a href="41001i120.htm" title="Flecainide">Flecainide</a></li><li><a href="41001i55.htm" title="Lidocaine">Lidocaine</a></li><li><a href="41001i125.htm" title="Propafenone">Propafenone</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i115.htm">Previous: Sodium Bicarbonate</a> | <a class="top" href="41001i116.htm#">Top</a> | <a accesskey="]" href="41001i1176.htm">Next: Dronedarone</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>